Cogent Biosciences, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Cogent Biosciences, Inc. - overview
Established
2014
Location
Waltham, MA, US
Primary Industry
Biotechnology
About
Based in Massachusetts, US, and founded in 2014 and led by CEO Andrew Robbins, Cogent Biosciences, Inc. operates as a biopharmaceutical company that develops cellular immunotherapies for the treatment of cancer. As of 2024, the company is traded at Nasdaq exchange with ticker symbol COGT. In February 2024, Cogent Biosciences, Inc.
raised USD 225 million in PIPE funding led by Commodore Capital, with participation from Fairmount Funds Management, Venrock Healthcare Capital Partners. Cogent Biosciences, Inc. developed a product known as bezuclastinib, which is a selective inhibitor targeting exon 17 mutations within the KIT receptor tyrosine kinase, including the KIT D816V mutation. It supports mutation in Systemic Mastocytosis, a rare disease characterized by the accumulation of mast cells in various organs.
The company’s product also developed for advanced gastrointestinal stromal tumors (GIST), which are for oncogenic KIT signaling. In addition, the firm’s drug is in early clinical results in Phase 1/2 trials, for treating cancer. The company plans to use the funding from February 2024 to fund research and development, activities relating to bezuclastinib and other product candidates, as well as for working capital and general corporate purposes.
Current Investors
Square 1 Bank, Atlas Venture, OrbiMed Advisors
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Molecular Science, Genetics & Gene Therapy, Oncology/Cancer Treatment, Pharmaceutical Research & Development
Website
www.cogentbio.com
Company Stage
Mature
Total Amount Raised
Subscriber access only
Cogent Biosciences, Inc. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| PIPE | Completed | Cogent Biosciences, Inc. | - |
Displaying 1 - 1 of 1
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.